Protein kinase inhibitors represent a major advance in cancer treatment due to their ability to target the specific kinases involved in tumor growth and survival. More than 80 small-molecule protein ...

HIGHLIGHTSAmplia’s lead drug narmafotinib enhances the activity of kRAS inhibitors in multiple preclinical cancer models presented at US ...

Few effective treatments exist to treat neurodegenerative diseases such as Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS). 1 Existing treatments focus on ...

Patients with rheumatoid arthritis (RA) tolerated a novel Janus kinase/Roh-associated protein kinase (JAK-ROCK) inhibitor without typical side effects. Phase 2 clinical trial at nine hospitals and ...

- Pre-NDA Meeting to discuss requirements for a 505(b)(2) NDA submission for IkT-001Pro in up to eight blood and stomach cancer indications - - Bioequivalence to 400 mg and 600 mg imatinib mesylate ...

Kinases are crucial to many signaling pathways, and when they don't work properly, the consequences can lead to problems, including cancer, immune diseases, and neurological disorders. But there are ...

Phase II Study of Samotolisib in Children and Young Adults With Tumors Harboring Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Pathway Alterations: Pediatric MATCH APEC1621D In a RET-fusion ...

Explore new findings on ovarian cancer and how blocking focal adhesion kinase can enhance immune response in treatment.

Leishmaniasis belongs to the class of neglected tropical diseases (NTDs) that particularly affect people in the poorest tropical regions of the world. NTDs are less studied and therapeutically ...